IP Library Granted Patent US 12668818
Granted Patent B2
US 12668818 · App. 19/355,669 · Granted Jun 30, 2026

Muscle-specific expression cassettes

Inventors: Gary Owens (Durham, NC); Matt Jordan-Steele (Durham, NC)
Assignee: Precision BioSciences, Inc.
C12N15/86A61K48/0058C12N2750/14143C12N2830/008
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12668818
App. No.
19/355,669
Granted
Jun 30, 2026
Kind
B2
Abstract

The present disclosure encompasses nucleic acid expression constructs that regulate the expression of a heterologous protein specifically in muscle tissues (e.g., skeletal muscle and cardiac muscle tissue). In particular embodiments of the disclosure, muscle-specific expression constructs are described that encode a heterologous protein. These heterologous proteins can be any protein that is desired to be expressed in a muscle cell. In particular embodiments of the disclosure, proteins are described for the treatment of Duchenne Muscular Dystrophy (e.g., engineered nucleases such as engineered meganucleases).

Claims (4)

1 . A polynucleotide comprising a muscle-specific expression cassette comprising the nucleic acid sequence of SEQ ID NO: 86, wherein said polynucleotide is a recombinant adeno-associated virus 9 (AAV9) viral genome, wherein said muscle-specific expression cassette is flanked by a 5′ and inverted terminal repeat (ITR) sequence and a 3′ ITR sequence, and wherein said 5′ ITR sequence comprises a first D-sequence comprising the nucleic acid sequence of SEQ ID NO: 94 and said 3′ ITR sequence comprises a second D-sequence comprising the nucleic acid sequence of SEQ ID NO: 95.

2 . A recombinant AAV comprising said polynucleotide of claim 1 , wherein said AAV has an AAV9 capsid.

3 . A pharmaceutical composition comprising a pharmaceutically acceptable carrier and said polynucleotide of claim 1 .

4 . A pharmaceutical composition comprising a pharmaceutically acceptable carrier and said recombinant AAV of claim 2 .